Seven Eight Capital’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-7,645
| Closed | -$525K | – | 801 |
|
|
2024
Q2 | $525K | Buy |
+7,645
| New | +$510K | 0.05% | 508 |
|
|
2023
Q3 | – | Sell |
-9,540
| Closed | -$735K | – | 643 |
|
|
2023
Q2 | $735K | Buy |
+9,540
| New | +$761K | 0.12% | 232 |
|
|
2022
Q4 | – | Sell |
-7,063
| Closed | -$436K | – | 494 |
|
|
2022
Q3 | $436K | Sell |
7,063
-2,477
| -26% | -$156K | 0.09% | 310 |
|
|
2022
Q2 | $590K | Sell |
9,540
-9,569
| -50% | -$592K | 0.24% | 148 |
|
|
2022
Q1 | $1.14M | Buy |
19,109
+11,555
| +153% | +$739K | 0.15% | 196 |
|
|
2021
Q4 | $548K | Buy |
+7,554
| New | +$520K | 0.1% | 262 |
|
|
2021
Q2 | – | Sell |
-25,900
| Closed | -$1.51M | – | 631 |
|
|
2021
Q1 | $1.51M | Hold |
25,900
| – | – | 0.35% | 107 |
|
|
2020
Q4 | $1.51M | Buy |
25,900
+7,700
| +42% | +$465K | 0.34% | 108 |
|
|
2020
Q3 | $1.15M | Buy |
+18,200
| New | +$1.26M | 0.25% | 132 |
|
|
2020
Q2 | – | Sell |
-43,300
| Closed | -$3.24M | – | 415 |
|
|
2020
Q1 | $3.24M | Sell |
43,300
-216,172
| -83% | -$14.9M | 0.83% | 21 |
|
|
2019
Q4 | $16.9M | Buy |
259,472
+80,289
| +45% | +$5.23M | 0.89% | 6 |
|
|
2019
Q3 | $11.4M | Buy |
179,183
+91,700
| +105% | +$5.99M | 0.6% | 34 |
|
|
2019
Q2 | $5.91M | Sell |
87,483
-205,100
| -70% | -$13.5M | 0.31% | 99 |
|
|
2019
Q1 | $19M | Buy |
292,583
+39,800
| +16% | +$2.65M | 1% | 14 |
|
|
2018
Q4 | $15.8M | Buy |
252,783
+227,300
| +892% | +$15.9M | 0.89% | 19 |
|
|
2018
Q3 | $1.97M | Buy |
+25,483
| New | +$1.92M | 0.12% | 244 |
|
|
2018
Q1 | – | Sell |
-104,683
| Closed | -$7.5M | – | 430 |
|
|
2017
Q4 | $7.5M | Buy |
+104,683
| New | +$7.95M | 0.77% | 23 |
|
|
2017
Q2 | – | Sell |
-7,165
| Closed | -$487K | – | 602 |
|
|
2017
Q1 | $487K | Sell |
7,165
-53,600
| -88% | -$3.77M | 0.09% | 270 |
|
|
2016
Q4 | $4.35M | Buy |
60,765
+46,400
| +323% | +$3.45M | 0.87% | 8 |
|
|
2016
Q3 | $1.14M | Buy |
+14,365
| New | +$1.17M | 0.33% | 114 |
|
|
2016
Q2 | – | Sell |
-5,465
| Closed | -$502K | – | 582 |
|
|
2016
Q1 | $502K | Sell |
5,465
-9,800
| -64% | -$884K | 0.21% | 151 |
|
|
2015
Q4 | $1.54M | Buy |
15,265
+11,800
| +341% | +$1.23M | 1.05% | 1 |
|
|
2015
Q3 | $340K | Buy |
3,465
+1,800
| +108% | +$200K | 0.3% | 116 |
|
|
2015
Q2 | $195K | Buy |
+1,665
| New | +$182K | 0.23% | 158 |
|
|
2015
Q1 | – | Sell |
-2,665
| Closed | -$251K | – | 565 |
|
|
2014
Q4 | $251K | Buy |
+2,665
| New | +$276K | 0.42% | 84 |
|
Other funds holding GILD
Seven Eight Capital's GILD Position: Q3 2024 in Review
Seven Eight Capital sold out of Gilead Sciences (GILD) in Q3 2024, closing a stake of 7,645 shares — an estimated $525K sold.
Seven Eight Capital first reported a position in GILD in Q4 2014 and held it in 25 quarters. The position peaked at $19M in Q1 2019. 1,719 funds tracked by Wall St. Rank hold GILD as of Q3 2024.
- Seven Eight Capital reported no remaining Gilead Sciences position as of Q3 2024 after selling out during the quarter.
- Seven Eight Capital sold 7,645 Gilead Sciences shares in Q3 2024, an estimated $525K.
- Seven Eight Capital first reported a position in Gilead Sciences in Q4 2014 and held it in 25 quarters.
- Seven Eight Capital's Gilead Sciences position peaked at $19M in Q1 2019.
- 1,719 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2024.
Based on Seven Eight Capital's 13F filing for Q3 2024, filed 12 Nov 2024.